The pull-back is to be expected given the $3.5M CR @17c in Dec21. Some Sophs may be keen to cash in on gains given market uncertainties. And while we've got great newsflow coming, there's still a way to go with toxicity tests (all indications are good) and regulatory hurdles for some key verticals. US patent approval and the 9-month grain storage efficacy study are major milestones on the journey to commercialisation. If you're losing faith, read more @stevenjd, the Biogene muse. GLTAH R-7
BGT Price at posting:
25.5¢ Sentiment: None Disclosure: Held
